Generated by AI
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services. Its core offering is Galleri, a blood-based screening test designed to detect multiple cancer types before symptoms appear, supporting earlier clinical evaluation and diagnosis. The company uses next-generation sequencing, machine learning, software, and automation to analyze biological signals associated with cancer and deliver screening insights through laboratory and service workflows. GRAIL serves healthcare providers and patients in the United States and international markets, with its work centered on cancer screening, diagnostic support, and related laboratory services. Headquartered in Menlo Park, California, GRAIL plays a notable role in the expanding field of liquid biopsy and genomic diagnostics, where it contributes to efforts aimed at improving early cancer detection and broadening access to advanced screening technologies.
Website250 S. Mathilda Avenue
Sunnyvale, CA, 94086
United States
The latest articles about GRAL.
GRAIL Inc (GRAL) eyes early 2027 FDA approval for Galleri after a favorable advisory committee vote, even as revenue growth slows and losses widen.
Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.
Summary of Oct 6's posts. Generated by AI.
Summary of Sep 24's posts. Generated by AI.
Summary of Feb 20's posts. Generated by AI.
Summary of Sep 24's posts. Generated by AI.
Investors talking about GRAL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.